Page 29 - 78 glossary of hivaids-related terms_opt

HIV-1 subtype M contains clades A through H, J, and K. Clades B
and C account for the majority of HIV infections around the world.
See Also: Subtype
C
Class-Sparing Regimen
An anti-HIV drug regimen that purposefully does not include one
or more classes of anti-HIV drugs. A class-sparing regimen may
be prescribed to save certain classes of drugs for later use or to
avoid side effects specific to a class. For example, a PI-sparing
regimen would not include any PIs. Because some PIs may cause
an increase in cholesterol in the blood, a PI-sparing regimen might
be prescribed for an HIV-infected person who already has high
cholesterol levels.

Clinical Alert
The National Institutes of Health (NIH) publishes these electronic
bulletins containing urgent early results of clinical trials. The data in
these bulletins warn about possible morbidity (sickness rates) and
mortality (death rates) in participants involved in the clinical trials.

Clinical Endpoint
A measurement used in clinical trials to evaluate the effect of the
treatment being tested. Examples of clinical endpoints for HIV
disease include death, serious drug toxicity, or development of an
AIDS-defining illness. Because these endpoints may be difficult to
measure without long-term follow-up, surrogate (substitute) short-
term endpoints, such as a change in viral load or CD4 count, may
also be used as clinical endpoints.
See Also: Clinical Trial

Clinical Failure
The occurrence or recurrence of HIV-related infections or a decline
in physical health despite taking an HIV treatment regimen for a
minimum of 3 months. Clinical failure may occur as a result of
virologic or immunologic failure.
See Also: Virologic Failure
Immunologic Failure

HIV/AIDS Glossary 27